Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1”

388 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 388 results

Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Not applicableUnknownNCT03078959
What this trial is testing

Prognostic Value of PD-L1 in NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 350
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Testing effectiveness (Phase 2)UnknownNCT05311566
What this trial is testing

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Who this might be right for
Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1+6 more
Lei Li 92
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Not applicableNot Yet RecruitingNCT07643688
What this trial is testing

Expression of Inflammatory Markers in the Course of Acute Respiratory Viral Infections

Who this might be right for
SARS CoV 2 InfectionRSV InfectionsInfluenza Infection
Fabiana Sherine Ganem dos Santos 150
Large-scale testing (Phase 3)Study completedNCT02551159
What this trial is testing

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
AstraZeneca 823
Testing effectiveness (Phase 2)Study completedNCT00882869
What this trial is testing

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Advanced Hepatocellular Carcinoma
Aegera Therapeutics 75
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Testing effectiveness (Phase 2)UnknownNCT04014101
What this trial is testing

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04911517
What this trial is testing

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Who this might be right for
Colorectal Neoplasms
Beijing Friendship Hospital 50
Testing effectiveness (Phase 2)Study completedNCT02674061
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 376
Not applicableUnknownNCT04922541
What this trial is testing

Multi-center Observational Study on the Progression of Atherosclerotic Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Who this might be right for
Plaque, AtheroscleroticProgrammed Cell Death Protein 1 Inhibitor
Second Affiliated Hospital, School of Medicine, Zhejiang University 50
Large-scale testing (Phase 3)Study completedNCT03833167
What this trial is testing

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Who this might be right for
Carcinoma, Squamous Cell
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Large-scale testing (Phase 3)Study completedNCT01905657
What this trial is testing

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 1,034
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Testing effectiveness (Phase 2)UnknownNCT05310383
What this trial is testing

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CarcinomaMetastatic Cervical CarcinomaPersistent Cervical Carcinoma+7 more
Lei Li 58
Early research (Phase 1)Study completedNCT02964013
What this trial is testing

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Who this might be right for
Neoplasms
Merck Sharp & Dohme LLC 474
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Load More Results